Cerapedics awarded group purchasing agreement with Premier for I-Factor

199
Cerapedics I-Factor
Cerapedics I-Factor

Cerapedics has been awarded a group purchasing agreement with Premier, a healthcare improvement company.

The new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for I-Factor peptide-enhanced bone graft. The contract is effective December 1, 2016.

“We are pleased to announce our new agreement with Premier because it will help us provide a growing number of surgeons with the advanced biologic they need to stimulate a natural bone healing process in patients with degenerative cervical disc disease,” says Glen Kashuba, chief executive officer of Cerapedics. “We look forward to the continued expansion of I-Factor bone graft commercialisation into the new year.”

I-Factor bone graft is based on synthetic small peptide (P-15) technology developed by Cerapedics to support bone growth through cell attachment and activation. Supported by Level I human clinical data, I-Factor bone graft received Premarket Approval (PMA) from the US Food and Drug Administration (FDA) in November 2015.

Premier’s alliance comprises approximately 3,750 US hospitals and 130,000 other provider organisations.

LEAVE A REPLY